Still life of Wegovy, an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity.
Michael Siluk | UCG | Getty Images
Novo Nordisk’s Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug.
The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. Weekly injections of Wegovy slashed the overall risk of heart attack, stroke, and death from cardiovascular causes by 20%, according to detailed results from the trial presented Saturday at the American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine. Novo Nordisk disclosed topline data from the study in August.
The findings could expand insurance coverage of…
2023-11-11 08:30:01
Article from www.cnbc.com